Therapeutic potential of GnRH antagonists in the treatment of precocious puberty

Bibliography

• WILDT L, MARSHALL G, KNOBIL E: Experimental induction of puberty in the infantile female rhesus monkey. Science (1980) 207:1373–1375.
   PubMed Web of Science ®Google Scholar
• GRUMBACH MM, STYNE DM: Puberty: ontogeny, neuroendocrinology, physiology, and disorders. In: Williams Textbook of Endocrinology (9th edn). Wilson JD, Foster DW, Kronenberg HM & Larsen PR (Eds), W.B. Saunders, Philadelphia, USA. (1998) 1509–1625.
   Google Scholar
• HERMAN-GIDDENS M, SLORA EJ, WASSERMAN RC et al.: Secondary sexual characteristics and menses in young girls seen in office practice: a study from the pediatric research in office settings network. Pediatrics (1997) 99:505–512.
   PubMed Web of Science ®Google Scholar
• KLEIN KO KA: Editorial: precocious puberty: who has it? Who should be treated? J. Clio. Endocrinol Metab. (1999) 84:411–414.
   PubMed Web of Science ®Google Scholar
• LEVINE MA: Clinical implications of genetic defects in G proteins: oncogenic mutations in Gas as the molecular basis for the McCune-Albright syndrome. Arch. Med. Res. (1999) 30:522–531.
   PubMed Web of Science ®Google Scholar
• HAVIV F, BUSH EN, KNITTLE J, GREER J: LHRH antagonists. Pharm. Biotechnol (1998) 11:131–149.
   PubMedGoogle Scholar
• •Important review about development and characteristics of different GnRH antagonists.
   Google Scholar
• OOSTDIJK W, DROP SL, ODINK RJ, HUMMELINK R, PARTSCH CJ, SIPPELL WG: Long-term results with a slow-release gonadotrophin-releasing hormone agonist in central precocious puberty. Dutch-German Precocious Puberty Study Group. Acta Paediatr. Scand. Sapp]. (1991) 372:39–45.
   Google Scholar
• PESCOVITZ OH, BARNES KM, CUTLER GB JR: Effect of deslorelin dose in the treatment of central precocious puberty. .1. Clio. Endocrinol Metab. (1991) 72:60–64.
   PubMed Web of Science ®Google Scholar
• CAREL JC, ROGER M, ISPAS S et al: Final height after long-term treatment with triptorelin slow release for central precocious puberty: importance of statural growth after interruption of treatment. French study group of Decapeptyl in precocious puberty.' Clio. Endocrinol Metab. (1999) 84:1973–1978.
   PubMed Web of Science ®Google Scholar
• PARTSCH CJ, HEGER S, SIPPELL WG:Management and outcome of central precocious puberty. Clio. Endocrinol ( 2002) 56:129–148.
   PubMed Web of Science ®Google Scholar
• PLOSKER GL, BROGDEN RN: Leuprorelin - A review of its pharmacology and therapeutic use in prostatic cancer, endometriosis and other sex hormone-related disorders. Drugs (1994) 48:930–967.
   PubMed Web of Science ®Google Scholar
• COOK T, SHERIDAN WP: Development of GnRH antagonists for prostate cancer: new approaches to treatment. Oncologist (2000) 5:162–168.
   PubMedGoogle Scholar
• COMARU-SCHALLY AM, BRANNAN W, SCHALLY AV, COLCOLOUGH M, MONGA M: Efficacy and safety of luteinizing hormone-releasing hormone antagonist cetrorelix in the treatment of symptomatic benign prostatic hyperplasia. Clio. Endocrinol Metab. (1998) 83:3826–3831.
   PubMed Web of Science ®Google Scholar
• ALBANO C, FELBERBAUM RE, SMITZ Jet al.: Ovarian stimulation with HMG: results of a prospective randomized Phase III European study comparing the luteinizing hormone-releasing hormone (LHRH)-antagonist cetrorelix and the LHRH-agonist buserelin. Hum. Reprod. (2000) 15:526–531.
   Google Scholar
• REISSMANN T, FELBERBAUM R, DIEDRICH K, ENGEL J, COMARU-SCHALLY AM, SCHALLY AV: Development and applications of luteinising hormone-releasing hormone antagonists in the treatment of infertility: an overview. Hum. Reprod. (1995) 10:1974–1981.
   PubMed Web of Science ®Google Scholar
• Cetrorelix Cetrotide° The Antagonist. Product Monograph (1999) 20–21.
   Google Scholar
• MORALE MC, BATTICANE N, BARTOLONI G et al: Blockade of central and peripheral luteinizing hormone-releasing hormone (LHRH) receptors in neonatal rats with a potent LHRH-antagonist inhibits the morphofunctional development of the thymus and maturation of the cell-mediated and humoral immune responses. Endocrinology (1991) 128:1073–1085.
   PubMed Web of Science ®Google Scholar
• PHILLIPS A, HAHN DW, MC GUIRE JL et al.: Evaluation of the anaphylactoid activity of a new LHRH antagonist. Life Science (1988) 43:883–888.
   Google Scholar
• ASLAM H, ROSIEPEN G, KRISHNAMURTHY H et al: The cycle duration of the seminiferous epithelium remains unaltered during GnRH antagonist-induced testicular involution in rats and monkeys.' Endocrinol. (1999) 161:281–288.
   Web of Science ®Google Scholar
• ROTH C, LEONHARDT S, SEIDEL C, LAKOMEK M, WUTTKE W, JARRY H: GnRH antagonist cetrorelix prevents sexual maturation of peripubertal male rats. Exp. Clin. Endocrinol. Diabetes (2000) 108:358–363.
   PubMed Web of Science ®Google Scholar
• •Inhibition of the pituitary-gonadal axis by GnRH antagonist in male rats.
   Google Scholar
• ROTH C, LEONHARDT S, THEILING K, LAKOMEK M, JARRY H, WUTTKE W: Ontogeny of the GnRH-, glutaminase-and glutamate decarboxylase-gene expression in the hypothalamus of female rats. Dev. Brain Res. (1998) 110:105–114.
   PubMedGoogle Scholar
• BOURGUIGNON JP, FRANCHIMONT P: Puberty-related increase in episodic LHRH release from rat hypothalamus in vitro. Endocrinology(1984) 114:1941–1943.
   PubMed Web of Science ®Google Scholar
• BOURGUIGNON JP, GERALD A, FRANCHIMONT P: Maturation of the hypothalamic control of pulsatile gonadotropin-releasing hormone secretion at onset of puberty: II. Reduced potency of an inhibitory autofeedback. Endocrinology (1990) 127:2884–2890.
   Google Scholar
• ROTH C, LEONHARDT S, SEIDEL C, LUFT H, WUTTKE W, JARRY H: Comparative analysis of different puberty inhibiting mechanisms of two GnRH agonists and the GnRH antagonist cetrorelix using a female rat model. Pediati: Res. (2000) 48:468–474.
   PubMed Web of Science ®Google Scholar
• •Effects of GnRH agonist versus GnRH antagonist in peripubertal female rats.
   Google Scholar
• ROTH C, SCHRICKER M, LAKOMEK M et al.: Autoregulation of the GnRH system during puberty: effects of antagonistic versus agonistic GnRH analogues in a female rat model. J. Endocrinol. (2001) 169:361–371.
   PubMed Web of Science ®Google Scholar
• •Extrapituitary effects of antagonistic versus agonistic GnRH analogues in female rats.
   Google Scholar
• HAISENLEDER DJ, COX ME, PARSONS SJ, MARSHALL JC: Gonadotropin-releasing hormone pulses are required to maintain activation of mitogen-activated protein kinase: role in stimulation of gonadotrope gene expression. Endocrinology (1998) 139:3104–3111.
   PubMed Web of Science ®Google Scholar
• LOUMAYE E, NAOR Z, CATT KJ: Binding affinity and biological activity of gonadotropin releasing hormone agonists in isolated pituitary cells. Endocrinology (1982) 111:730–736.
   PubMed Web of Science ®Google Scholar
• TSUTSUMI M, LAWS SC, RODIC V, SEALFON SC: Translational regulation of the gonadotropin-releasing hormone receptor in alphaT3-1 cells. Endocrinology (1995) 136:1128–1136.
   PubMed Web of Science ®Google Scholar
• SEONG JY, JARRY H, KUHNEMUTH S, LEONHARDT S, WUTTKE W, KIM K: Effect of GABAergic compounds on gonadotropin-releasing hormone receptor gene expression in the rat. Endocrinology (1995)136:2587–2593.
   PubMed Web of Science ®Google Scholar
• KANG SK, CHOI KC, CHENG KW, NATHWANI PS, AUERSPERG N, LEUNG PC: Role of gonadotropin-releasing hormone as an autocrine growth factor in human ovarian surface epithelium. Endocrinology (2000) 141:72–80.
   PubMed Web of Science ®Google Scholar
• RAGA F, CASAN EM, KRUESSEL JS et al:Quantitative gonadotropin-releasing hormone gene expression and immunohistochemical localization in human endometrium throughout the menstrual cycle. Biol. Reprod. (1998) 59:661–669.
   PubMed Web of Science ®Google Scholar
• HARRIS N, DUTLOW C, EIDNE K, DONG KW, ROBERTS J, MILLAR R: Gonadotropin-releasing hormone gene expression in MDA-MB-231 and ZR-75-1 breast carcinoma cell lines. Cancer Res. (1991) 51:2577–2581.
   PubMed Web of Science ®Google Scholar
• EMONS G, ORTMANN 0, BECKER M et al: High affinity binding and direct antiproliferative effects of LHRH analogues in human ovarian cancer cell lines. Cancer Res. (1993) 53:5439–5446.
   PubMed Web of Science ®Google Scholar
• EMONS G, SCHRODER B, ORTMANN 0, WESTPHALEN S, SCHULZ KD, SCHALLY AV: High affinity binding and direct antiproliferative effects of luteinizing hormone-releasing hormone analogs in human endometrial cancer cell lines. J. Clin. Endocrinol. Metab. (1993) 77:1458–1464.
   PubMed Web of Science ®Google Scholar
• SCHALLY AV: Luteinizing hormone-releasing hormone analogs: their impact on the control of tumorigenesis. Peptides (1999) 20:1247–1262.
   PubMed Web of Science ®Google Scholar
• SRKALOVIC G, WITTLIFF JL, SCHALLY AV: Detection and partial characterization of receptors for [D-Trp6]-luteinizing hormone-releasing hormone and epidermal growth factor in human endometrial carcinoma. Cancer Res. (1990) 50:1841–1846.
   PubMed Web of Science ®Google Scholar
• EMONS G, MOLLER V, ORTMANN 0, SCHULZ KD: Effects of LHRH-analogues on mitogenic signal transduction in cancer cells. Steroid Biochem. Mol. Biol. (1998) 65:199–206.
   PubMed Web of Science ®Google Scholar
• HAN XB, CONN PM: The role of protein kinases A and C pathways in the regulation of mitogen-activated protein kinase activation in response to gonadotropin-releasing hormone receptor activation. Endocrinology (1999) 140:2241–2251.
   PubMed Web of Science ®Google Scholar
• LIN X, CONN PM: Transcriptional activation of gonadotropin-releasing hormone (GnRH) receptor gene by GnRH: involvement of multiple signal transduction pathways. Endocrinology (1999) 140:358–364.
   PubMed Web of Science ®Google Scholar
• KRSMANOVIC LZ, MARTINEZ-FUENTES AJ, ARORA KK et al.: Local regulation of gonadotroph function by pituitary gonadotropin-releasing hormone. Endocrinology (2000) 141:1187–1195.
   PubMed Web of Science ®Google Scholar
• •Autocrine regulation of hypothalamic and pituitary GnRH.
   Google Scholar
• FELEDER C, JARRY H, LEONHARDT S, MOGUILEVSKY JA, WUTTKE W: Evidence to suggest that gonadotrophin-releasing hormore inhibits its own secretion by affecting hypothalamic amino acid neuro-transmitter release. Neuroendocrinology (1996) 64:298–304.
   PubMed Web of Science ®Google Scholar
• PARTSCH CJ, PETER M, SIPPELL WG:Leuprorelin Depot zur Behandlung der progressiven Pubertas praecox vera. Monatsschr. Kinderheilkd. (1999) 147:638–647.
   Web of Science ®Google Scholar
• GRONDKER C, EMONS G: GnRH - mechanisms of action. In: GnRH analogues, the state of the art at the millennium Lunenfeld B (Ed), Parthenon Publishing, Carnforth, UK (1999):7–29.
   Google Scholar
• GRONDKER C, VOLKER P, SCHULZ KD, EMONS G: Luteinizing hormone-releasing hormone agonist triptorelin and antagonist cetrorelix inhibit EGF-induced c-fos expression in human gynecological cancers. Cynecol Once] (2000) 78:194–202.
   PubMed Web of Science ®Google Scholar
• •Signal transduction in cancer cells, effects of GnRH agonists and antagonists.
   Google Scholar
• BEHRE HM, KLIESCH S, POHSE G, REISSMANN T, NIESCHLAG E: High loading and low maintenance doses of a gonadotropin-releasing hormone antagonist effectively suppress serum luteinizing hormone, follicle-stimulating hormone, and testosterone in normal men. I. Clin. Endocrine] Metab. (1997) 82:1403–1408.
   PubMed Web of Science ®Google Scholar
• MCLEOD D, ZINNER N, TOMERA K et al.: A Phase III, multicenter, open-label, randomized study of abarelix versus leuprolide acetate in men with prostate cancer. Urology (2001) 58:756–761.
   PubMed Web of Science ®Google Scholar
• BROQUA P, RIVIERE PJ, CONN PM, RIVIER JE, AUBERT ML, JUNIEN JL: Pharmacological profile of a new, potent, and long-acting gonadotropin-releasing hormone antagonist: degarelix.f Phannacel Exp. Ther. (2002) 301:95–102.
   PubMed Web of Science ®Google Scholar
• •Effects of a new long-acting GnRH antagonist.
   Google Scholar
• ASHTON WT, SISCO PM, KIECZYKOWSKI GR et al.: Orally bioavailable, indole-based nonpeptide GnRH receptor antagonists with high potency and functional activity. Bieerg. Med. Chem. Lett. (2001) 11:2597–2602.
   PubMed Web of Science ®Google Scholar
• MILLAR RP, ZHU YF, CHEN C, STRUTHERS RS: Progress towards the development of non-peptide orally-active gonadotropin-releasing hormone (GnRH) antagonists: therapeutic implications. Br. Med. Bull. (2000) 56:761–772.
   PubMed Web of Science ®Google Scholar
• •Therapeutic implications of newly developed oral GnRH antagonists.
   Google Scholar